Oncotelic Opens BIO REBOOT Collaboration for AI-Assisted Drug Discovery
Published in Artificial Intelligence, Drugs development & discovery, Tools.
Oncotelic and its Pet2DAO subsidiary announced on October 5, 2026 that scientists, AI developers and biotech founders can register for BIO REBOOT, a collaboration initiative linked to the PDAOAI drug-discovery platform.
Registration is free. Selected projects may be considered for funding and support with validation, formulation, regulatory planning and clinical development. The company specifies that support depends on scientific review, available resources and agreed terms.
PDAOAI uses biomedical abstracts to generate candidate targets and testable hypotheses. Its Partitioned Literature Aggregation method analyses disease-specific literature groups separately before combining findings, aiming to reduce distortions from differences in publication volume.
The announcement accompanies presentations scheduled for October 7–9 at Drug Discovery 2026, including a candidate four-gene signature for hepatocellular carcinoma. This is a research hypothesis and collaboration announcement, rather than clinical validation of a biomarker or treatment.
Source: Oncotelic press release, October 5, 2026. BIO REBOOT registration.